1380445-11-3

Basic information

• Product Name: 4-(((1R,2S)-2,3-dihydro-1-hydroxy-2-(1H-inden-2-yl)-1H-inden-2-yl)methyl)benzoic acid
• Synonyms: 4-(((1R,2S)-2,3-dihydro-1-hydroxy-2-(1H-inden-2-yl)-1H-inden-2-yl)methyl)benzoic acid
• CAS NO: 1380445-11-3
• Molecular Weight: 382.459
• Mol File: 1380445-11-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(((1R,2S)-2,3-dihydro-1-hydroxy-2-(1H-inden-2-yl)-1H-inden-2-yl)methyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(((1R,2S)-2,3-dihydro-1-hydroxy-2-(1H-inden-2-yl)-1H-inden-2-yl)methyl)benzoic acid(1380445-11-3)
• EPA Substance Registry System: 4-(((1R,2S)-2,3-dihydro-1-hydroxy-2-(1H-inden-2-yl)-1H-inden-2-yl)methyl)benzoic acid(1380445-11-3)

Safety Data

• Hazardous Substances Data: 1380445-11-3(Hazardous Substances Data)

Upstream product

• 31928-64-0 1-trimethylsilyloxy-3H-indene 
• 192194-67-5 methyl 4-((2,3-dihydro-2-(1H-inden-2-yl)-1-oxo-1H-inden-2-yl)methyl)benzoate 

Relevant articles and documents

6-(Methylamino)hexane-1,2,3,4,5-pentanol 4-(((1 S,2 S)-1-hydroxy-2,3- dihydro-1 H,1′ H -[2,2-biinden]-2-yl)methyl)benzoate (PH46A): A novel small molecule with efficacy in murine models of colitis

The indane skeleton is found naturally and in several therapeutic molecules in medicinal chemistry. During our work on the anti-inflammatory activity of naturally occurring and synthetic indanes, we have synthesized a novel indane scaffold that has been optimized for both anti-inflammatory activity and bioavailability. We have evaluated our lead molecule, PH46A, in in vivo models of inflammatory bowel disease (IBD), an area of considerable unmet clinical need; current therapies are often unable to control the course of the disease. The compound significantly reduced histological damage and serum amyloid A (SAA) levels in IL-10-/- colitis mice, was efficacious in the 5% dextran sulfate sodium (DSS) colitis model, and compared favorably with prednisolone in this model and supports its potential use to treat acute exacerbations of the disease. Further, the graded response to the compound may also lend itself to be used at a lower dose to maintain periods of remission.

INDENE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

Described are compounds of the structural formula (I): Also provided are pharmacologically acceptable isomers and salts of the compound of (I). The compounds are useful in the treatment of inflammatory bowel disease.